Lipid-lowering antidiabetic agent
A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.
1. A method of treating a prediabetic condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a metformin salt of a polyunsaturated fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and mixtures thereof.
2. The method of claim 1 , wherein the pharmaceutical composition has an aqueous solubility of at least 50 mg/ml under standard conditions.
3. The method of claim 1 , wherein the subject has serum triglyceride levels of greater than 200 mg/dl.
4. The method of claim 1 , wherein the subject has hypertriglyceridemia.
5. The method of claim 1 , wherein the metformin salt of a polyunsaturated fatty acid is a polymorph, solvate, or hydrate.
6. The method of claim 1 , wherein the subject is further selected from the group consisting of subjects having or at risk of developing diabetes, a prediabetic condition, obesity, cardiac arrhythmia, myocardial infarction, and stroke due to high serum triglyceride levels.
7. The method of claim 1 , wherein the prediabetic condition is incipient diabetes with impaired glucose tolerance.
8. The method of claim 1 , wherein the polyunsaturated fatty acid is eicosapentaenoic acid (EPA).
9. The method of claim 1 , wherein the polyunsaturated fatty acid is docosahexaenoic acid (DHA).
10. The method of claim 1 , wherein the polyunsaturated fatty acid is a mixture of EPA and DHA.